• Red White & Bloom has officially entered Phase 2 of an aggressive three-phase expansion plan in Florida
• Phase 2 involves the installation and commissioning of 30 customized, self-contained growing pods
• RWB recently received OMMU approval for the first five pods that it subsequently installed and commissioned
• The company, through its Red White & Bloom Florida LLC subsidiary, produced the first batch of chocolates from the new Sanderson production facility, making substantial progress since launching the greenhouse facility in Apopka in late September

Following the early October completion of phase one of a three-phase development strategy that captures Red White & Bloom Brands’ (CSE: RWB) (OTCQX: RWBYF) expansion plan in Florida, the company has officially entered the second phase. This announcement follows the receipt of an Office of Medical Marijuana Use (“OMMU”) approval on October 22 that sanctioned the installation, commissioning, and loading of five of 30 planned modular grow pods. With the five approved pods already growing plants, RWB, through its subsidiary Red White & Bloom Florida LLC (“RWBFL”), is fast-tracking the remaining 25 pods with the expectation that they will be operational no later than the first of December. Combined, the 30 16’ by 40’ customized, self-contained pods will provide about 19,000 square feet of operating space. Each pod will be capable of producing 63 pounds of sellable product per harvest, while collectively, they are expected to produce 10,000 pounds of high-quality flower annually. RWB anticipates that the annual yield will generate $30 million in additional revenue. “The grow pods provide us with speed to market capabilities, which are needed for RWBFL to meet and exceed expectations for generating profitable revenue early in 2022,” commented Jim Frazier, GM of RWB Florida. According to Brad Rogers, Red White & Bloom CEO, the RWBFL team has been on time, on target, and under budget in executing each step of the development strategy for the two cultivation centers in Apopka and Sanderson. “Coupled with our cultivation and processing in Sanderson, the additional product [from the pods] will ensure Red White & Bloom has the needed inventory to fulfill inventory requirements at our HT Medical Cannabis dispensary in Springhill and for the next three dispensaries opening in the first quarter of 2022. The locations of the three dispensaries are St. Petersburg, Daytona, and Miami Beach,” Rogers continued. In addition to the activation of the five pods, RWB announced its subsidiary had achieved another milestone with the production of the first batch of chocolates from its new Sanderson production facility. Announced on September 9, the facility was built out to GMP specifications to capitalize on Florida’s burgeoning cannabis derivative market, which is expected to reach $2 billion in annual sales by 2025 from a projected $1.3 billion in 2021 (https://ibn.fm/0DTzt). RWB also reported that its subsidiary had made significant progress since launching the 45,000 square foot greenhouse in Apopka in late September (https://ibn.fm/NTeGX). Half of the greenhouse is utilized for auto flower production for biomass to support RWBFL’s extraction operation in the future. The remaining half is reserved for mother plants, clones, and vegetative operations for RWB’s proprietary genetic strains. Moreover, RWBFL has hired highly talented cultivation specialists to enable aggressive growth and fulfill a Q4 harvest schedule. By yearend, the subsidiary expects to have expanded its current team of 15 to 25 and then to 50 by the end of Q1 2021. Prospective employees can view job openings via https://ibn.fm/7OTPm. The three-phased development strategy aligns perfectly with Rogers’ summary of the company’s focus for the remainder of 2021 and throughout 2022 (https://ibn.fm/2A0IF). “The company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses, and the synergies from our M&A success,” stated Rogers. Notably, Phase 3, which is on schedule, will focus on increasing the cultivation capacity in Sanderson as well as building out the remaining space in Apopka to enable RWBFL to generate profitable revenue by maximizing the two facilities. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

Date: November 16-18, 2021  Virtual Event Roth Capital Partners is proud to announce its 10th annual technology event: the Roth Technology and AgTech Answers Virtual Event.  Scheduled for November 16-18, 2021, the event is aimed at investors, offering them the chance to hear from and meet with executive management from private and public companies covering a range AgTech and Technology sub-sectors. This year’s event will be highlighted by virtual one-on-one/small group meetings, coupled with two industry panels. These small group discussions will be held throughout the 3-day event and primarily cover capital perspectives on AgTech. Leading investors in the sector will play an integral role in steering the discussions and offering insights and input into the industry dynamics for attendees. They will also be available for any questions that participants might have. The meetings will also feature 40-minute management-investor video conference calls. Here, clients will be offered extensive interaction with executive management to gain in-depth insights into a company of their interest. Additionally, the event’s two industry panels will discuss changemakers in agriculture today. Over 100 companies so far, including 22nd Century Group, AeroFarms and AgroFresh Solutions, Inc., have confirmed their participation in the event, sponsored by KPMG, Morrison Foerster and InvestorBrandNetwork (“IBN”). This year’s event reflects Roth’s overall theme and approach with its conferences. Featuring its signature format of Q&A sessions and one-on-one management meetings, it promises to offer value to attendees and help forge relationships designed to benefit the parties involved. In the past, Roth has held conferences covering various industries, from healthcare to energy and cannabis. This 10th annual technology event promises to be bigger and better than ever before. For those interested in the event visit https://ibn.fm/cwX4o, and see registration page at https://ibn.fm/kGo4C.

• Rich communication services (“RCS”) and big-data insights provider FingerMotion has seen revenue growth of 25 percent year-over-year in its mobile SMS and MMS services, according to recent quarterly financial analysis
• FingerMotion is beginning to record revenues in a third channel of operations thanks to its trademarked big data platform Sapientus, which is providing the foundation of an array of insurtech services
• China’s mobile payment use saw a sharp increase last year in response to the COVID pandemic and telecommunications products and services providers such as FingerMotion anticipate continued growth during the coming years
• China’s government is also encouraging development of its insurance industry services, providing optimism for continued demand for big data services such as Sapientus’ platform to help build the infrastructure

As mobile payments continue to inch their way upwards in China’s mature smartphone access market, communications technology solutions provider FingerMotion (OTCQX: FNGR) is building revenue growth and pursuing innovations to attract new users and increase engagement. FingerMotion noted in last month’s report on its Q2 financial position that quarterly growth in its SMS (texting) & MMS (phone photo, video and audio sharing) business revenue had hit 25 percent year over year. And growth in its Telecommunications Products and Services business revenue had reached 142 percent YOY. China’s population is expected to pass 750 million proximity mobile payment users (using a mobile phone to pay for goods or services while at a physical point-of-sale terminal) during the coming year and approach 800 million by 2025, with a gradual increase in the percentage of the globe-leading population doing so each year following a spike during the pandemic, according to Insider Intelligence analysts (https://ibn.fm/iKjms). The trend shows that mobile payments have become the country’s top payment method, especially in urban areas, according to Insider Intelligence. By 2025, around two-thirds of China’s consumers are expected to be using proximity mobile payments and peer-to-peer payments (“P2P”) as a regular course of business. FingerMotion expects to draw on the increased attention it has gained during consumers’ shift to increased digital traffic as a result of the COVID pandemic to continue building its user base, but the company is also turning its attention to the potential of its big data platform, Sapientus. Sapientus-related revenue has been in a nascent stage this year as the company develops its new services, but the appeal of the company’s unparalleled access to China’s consumers with over half a million transactions daily and its ability to readily draw on data to build the foundations of an insurtech industry have led to agreements such as the deal with global insurer Pacific Life to provide data for Pacific Life’s Re-insurance division. And the country’s government has encouraged further development of the insurance industry, as noted in the China Banking and Insurance Regulatory Commission’s recent statement encouraging an increase in services to gig-economy delivery workers, elderly people and children with congenital diseases and medical conditions (https://ibn.fm/kHyXc). That in turn is boosting expectations for big data revenue growth during the coming months. “This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams,” CEO Martin Shen stated when last month’s report was released (https://ibn.fm/NKhr8). “This quarter was more of a transition to greater profitability as more of our initiatives started contributing to gross margin.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced
• Program offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatment
• EMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework

In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing support and guidance in the space becomes even more important. With that in mind, Cybin (NEO: CYBN) (NYSE American: CYBN) has launched its proprietary EMBARK Psychedelic Facilitator Training Program (https://ibn.fm/3lzkp). Named for the program’s six clinical domains — Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, Keeping Momentum — the EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced in psychedelic treatment, as well as the equally broad training therapists need to facilitate the treatment. “Psychedelic medicines and the great healing potential they hold have only just begun to find their place in our culture and its array of therapeutic approaches,” explained Bill Brennan, a cocreator of the program. “EMBARK represents an important step forward in that process. “We designed it to be uniquely responsive to the distinctive and disruptive ways that these medicines heal people, while also able to incorporate synergistic aspects of other evidence-based treatments,” Brennan continued. “Its flexible, six-domain structure allows us to open the aperture on our notions of healing and expand our ability to help patients reach a place of wellness. We offer EMBARK in a spirit of service and deep respect for psychedelic medicines and the many avenues of healing they open to us.” Led by an expert team, the program offers psychedelic clinical trial facilitators the foundational training needed to provide skillful and ethical care to participants receiving psychedelic treatment. With an emphasis on experiential learning, the training will kick off with an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state. The training includes an experiential training component, in addition to the core training and practice sessions on the EMBARK model. Cybin’s EMBARK Psychedelic Facilitator Training Program is designed to prepare facilitators to work within the program’s six domains. The program enhances each facilitator’s individual therapeutic training and expertise by offering a flexible curriculum that emphasizes trauma-informed, culturally competent, and ethically rigorous care. “We’re excited to host this training,” said Dr. Alex Belser, EMBARK’s coauthor and Cybin chief clinical officer. “When we first created EMBARK, we canvassed 20 different psychedelic-assisted psychotherapies. We found that some therapies left out important aspects, like people’s spiritual experiences, somatic experiences or human relationships. “Patients were telling us that these experiences were central to their healing, but many therapies seemed to be missing critical pieces,” Dr. Belser continued. “To address this challenge, we developed EMBARK, which provides an open architecture to support the varieties of psychedelic experience within a coherent therapeutic framework. This is a patient-centered approach for the whole person.” Cybin is focused on progressing psychedelic therapeutics, making it an ideal advocate and sponsor of the EMBARK approach. A leading biotechnology company, Cybin is working to progress psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Plant community brand builder PlantX Life Inc. is a growing e-commerce hub with over 5,000 products reflecting its focus on plant-based foods, greenery, textiles, and other items
• The company recently opened a brick-and-mortar store in the San Diego, Calif., area, adding to locations in Venice Beach and the Vancouver, British Columbia area
• The company is preparing to next open stores in Tel Aviv, Israel, and then in a pair of malls in Ontario, near Canada’s legislative capital as part of its international upscaling
• PlantX Life’s weekly podcast series, YouTube channel videos, informative blog and e-commerce portal are a means of providing education on the lifestyle’s benefits not only to fans of plant-based products, but also those who have been reluctant to set foot inside a physical store where vegan items are sold

Plant-based lifestyle e-commerce hub PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has established a new outlet for its branded products with the grand opening of its new XMarket cafe and store in the San Diego area, joining PlantX’s physical store at Venice Beach (https://ibn.fm/YP7G7). The store has become part of the corporate family begun with the company’s flagship store and dining outlets in the Vancouver, British Columbia area, and will soon be joined by a store and web presence in Tel Aviv, Israel, then retail mall outlets in Toronto and Ottawa, Ontario (https://ibn.fm/2pGxU). The expanding footprint of the company’s XMarket store locations worldwide strengthens PlantX’s aim of diversifying its clientele as it also builds its e-commerce marketplace on a vision of becoming a one-stop shopping destination for the plant-based community, a megalith vegan Amazon. PlantX isn’t simply attempting to build retail channels. The company’s love of vegan and other plant-based interests is leading it to increase public knowledge of the wide spectrum of plant-based products, recipes, and lifestyle benefits, through educational channels such as its weekly podcast, blog and YouTube presence. “In plant-based living, there is a big challenge. For the people who don’t believe in a plant-based lifestyle, right away their back goes up a little bit about even entering into the store or in the environment,” PlantX Founder Sean Dollinger said during a September interview (https://ibn.fm/RYM74). “(XMarket partner) Matthew Kenney, arguably the No. 1 vegan chef in the world, … said it best. He said, ‘Why do you need to point out that it’s plant-based at the end of the day?’ And we’ve put a whole spin now on our markets calling it XMarket,” Dollinger added. “Now that it’s just called XMarket, why would you not go and explore and check it out? … We’ve tried to apply this concept to our e-commerce where (we’re focused on) getting people in the door. Let them just come, let them just try and we know that they’ll be hooked on it.” The blog’s recent entries have addressed topics such as the focus on vitamin B12 in a plant-based diet, the importance of including “superfoods” in meal choices, and non-food topics such as “Plant Variegation 101” and “Plant-Based Slang.” “A healthy body is one that has a healthy digestive system to break down and absorb all the nutrients it receives,” the Oct. 31 entry on tips for improving digestion begins (https://ibn.fm/pZb9v), coinciding with the day when millions of American children collect pre-packaged, sugar-and-fat-loaded candy treats during trick-or-treating. PlantX’s brand ecosystem has already made it a seller of more than 5,000 products in harmony with its love of all things plant-based, and the company aims to continue expanding into cosmetics, clothing and other product brands as well as food services. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Events industry and global live streaming, two markets that Friendable’s flagship offering, Fan Pass, can leverage, are expected to grow consistently over the next years
• The Fan Pass Live artist platform has been redesigned, with new apps released on prominent app stores
• Through the platform, artists get the opportunity to earn revenue in numerous ways doing what they love

The events industry was seemingly crippled by the events of 2020. With businesses closing, some permanently, nobody knew when people would be allowed in the same room, let alone a packed concert venue. Despite this, the industry is showing signs of getting back on track, being expected to continue growing over the next few years and reach $1.5 trillion by 2028. This marks a CAGR of 11.2% over the forecast period (2021-2028), up from its 2019 value of $1.1 trillion (https://ibn.fm/ClYa6). While the events industry was slowing down in 2020, the global live streaming market was picking up even more speed, continuing an impressive growing trend. The industry is expected to keep on expanding at an impressive rate, as demand for diverse, quality digital content is only growing. Global live streaming is therefore projected to reach $247.28 billion by 2027, growing at a CAGR of 28.1% (https://ibn.fm/rgNjN). With its unique Fan Pass Live Streaming artist platform, mobile technology and marketing company  Friendable (OTC: FDBL) is uniquely positioned to leverage both these markets and take advantage of their opportunities for growth – appealing to those who want to stay home and watch entertainment and eventually providing the option for exclusive in-person events. Friendable released its flagship offering, Fan Pass, in July 2020 as a platform for artists to share their work and fans to get a front-row seat to the action from the comfort of their home. Since then, the platform has grown considerably, both in terms of number of artist members and fans, as well as in terms of available services and offerings for its users. During the latter part of 2021, the company’s main focus has been to make the Fan Pass platform more visible and accessible. This effort included a redesign of the company’s website, and the launch of new Fan Pass apps on the Apple Store and Google Play. Now, the company is focusing on moving into 2022, offering artists and fans the best that music offers. Artists who sign up with the Fan Pass platform have the opportunity to take advantage of the unique revenue structure available. Artists earn by selling tickets to private events, monthly content views, and the merchandise they offer online. Friendable also sets up monthly contests for the artists to take part in – most recently, Double Down October provided double revenue for those artists who met the qualifications of the contest. Right now, the November contest is underway, and anyone who streamed on or before November 8 was eligible to enter. When becoming an artist on the Fan Pass platform, Friendable offers more than just a place for showcasing talent. The company has also incorporated a streaming gear store and an Artist Pro Services offering. Pro Services allow for artists to create logos, design merchandise, and the material to promote shows on social media platforms. Although these come at a cost, the Fan Pass platform offers three different tiers of products, with prices beginning at under $50. Artists can also enjoy these perks when they join the Fan Pass platform:

• Personal artist channel
• Live streaming and publishing controls
• Customized merchandise
• Custom logo design
• Social media designs
• Artist dashboard
• Maintaining complete control
• Being discovered by new fans

In the future, Friendable will be incorporating other features that will help with artist promotion and their revenue potential as well, such as non-fungible tokens (“NFTs”). Fans who sign up for Fan Pass get exclusive backstage and VIP access to their favorite artists – including a look at their daily lives. The monthly cost to join Fan Pass is less than you would pay for an MP3 download of your favorite song, but this way, you get an entire catalog of artist content at your fingertips. Fans also get access to artist live streams, exclusive merch, the ability to discover new music, and overall more ways to connect with their favorite artists. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Hedge funds with artificial intelligence capabilities showed competitive edge over investors that didn’t use AI
• Top reason given for using algorithms is to reduce market impact
• The fund offers investment opportunity capitalizing on crypto volatility and powered by proprietary trading algorithms

Artificial intelligence (“AI”) is entering the world of finance — with impressive results. According to a recent “Institutional Investor” article, hedge funds that use AI returned almost triple the global industry average (https://ibn.fm/XoDrA). With that as a backdrop, DigiMax Global’s (CSE: DIGI) (OTC: DBKSF) just-launched Cryptocurrency Hedge Fund could not have come at a better time. “Hedge funds with artificial intelligence capabilities showed a huge competitive edge over investors that didn’t use AI, new research indicates,” the article stated. “AI-led hedge funds produced cumulative returns of 34 percent in the three years through May, a report Tuesday from consulting and research firm Cerulli shows. That compares with a 12 percent gain for the global hedge fund industry over the same period.” The article quoted Justina Deveikyte, associate director of European institutional research at Cerulli: “There has long been suspicion of the ability of AI to react to unexpected events, such as the coronavirus pandemic. . . . “But there is now a sense that the technology has advanced to the point where it is better able to adapt to unforeseen scenarios via the ever-growing amount of market data available.” High volatility has always been part of the investment scene, with most investors understanding that risk. But that doesn’t stop them from looking for ways to lower that risk. A 2020 article released by “The Trade” reported that in an algorithmic trading survey taken before the COVID-19 pandemic, the top reason given for using algorithms is to reduce market impact (https://ibn.fm/SX2X1). “Given the increase in market volatility and trading volumes since March 2020, it is striking that the pandemic has led to a greater realization of algorithmic trading in the industry,” the article observed. “The industry has made positive steps toward beginning to refocus on the quality of execution and achieving better outcomes for the end investor, even though room for improvement remains. Initial concerns brought by The Markets in Financial Instruments Directive (MiFID II) have evolved from managing the compliance requirements particularly around best execution to fine-tuning algorithmic trading strategies as a major component of e-trading usage.” DigiMax’s CryptoCurrency Hedge Fund is representative of DIGI’s expertise in the AI world. The fund offers high net worth, institutional and family office clients a fully systematic long/short active investment into a basket of cryptocurrencies capitalizing on crypto volatility and powered by proprietary trading algorithms (https://ibn.fm/RsS6B). Led by an experienced investment and fund-management team, DigiMax’s actively managed fund provides an excellent opportunity for larger investors to gain exposure to cryptocurrencies in their portfolios. Through the use of CryptoDivine.ai and DigiMax’s artificial intelligence capabilities, investors can take advantage of the high volatility while reducing risk in this new fast-growing asset class. DigiMax is supporting its mission to empower investors to safely invest in cryptocurrencies by harnessing the power of artificial intelligence. The company is committed to unlocking the potential of disruptive technologies by providing advanced financial, predictive, and cryptocurrency solutions across various verticals. DigiMax reveals actionable predictive insight across the financial and human world. For more information, visit the company’s website at www.DigiMax-Global.com. NOTE TO INVESTORS: The latest news and updates relating to DBKSF are available in the company’s newsroom at https://ibn.fm/DBKSF

Date: December 15-16 2021 Online Livestream On December 15-16, 2021, pharma companies, medical vendors, and clinicians are invited to attend the 5th Virtual Clinical Trials conference, the industry’s most trusted and long-lasting conference on clinical trials. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. As clinical trials are switching to more decentralized and hybrid models, a collaborative platform for the exchange of information is vital to keep up with the rapid growth. At the 5th Virtual Clinical Trials Conference, hear from those on the front lines of these remote applications and discuss the future of clinical trials from leading pharma industry stalwarts. At this 2-day event, attendees can learn how to successfully conduct clinal trial operating procedures and protocol design and learn what major obstacles to avoid in data compliance. The speaking faculty consists of an eminent panel of dignitaries and pharma industry professional experts who will offer all-new insights on constructing and measuring endpoints, executing effective patient recruitment strategies, applying innovative technologies, and many other insightful strategies to ensure your next clinical trial is a success. Clinicians, trial managers, clinical data experts, vendors, pharma companies, and scientists should leverage the opportunity offered by the conference. Important topics of discussion include:

• Implement robust trial design techniques and SOPs to improve your internal processes
• Improve patient enrollment, safety monitoring, and follow up outcomes
• Enhance approaches to flexible protocol design in DCTs
• Increase collaboration measures to ensure quality in your decentralized approach
• Understand new and exciting technologies that will increase efficiencies in your trials

Adapt your organization to the virtual change at this 2-day event which will commence in a virtual setting from 8:30 am on 15th December. Attendees will hear how clinical trials are conducted in the European Union (“EU”) and the major changes clinical trials are facing around the globe. Other topics that will be discussed include standardizing safety operating procedures, understanding ways to eliminate duplicate data entry, and how eConsent helps with studies at the site, sponsor, and CROs level to achieve success. For more information, please visit https://ibn.fm/72Oh9.

• InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function
• With neurogenerative diseases affecting millions worldwide and the cost of treating patients expected to rise in the future, finding treatments and cures is a matter of increasing urgency
• InMed’s patent application is a promising start, expanding the company’s patent portfolio, which currently includes twelve patent families

InMed Pharmaceuticals (NASDAQ: INM), a global leader in the manufacturing and pharmaceutical development of rare cannabinoids, recently filed a Patent Cooperation Treaty (“PCT”) application, titled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids” (https://ibn.fm/wIQFy). This international patent application specifies a rare cannabinoid that may inhibit or slow the progression of neurogenerative diseases – such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, and others – by providing neuroprotection in a population of affected neurons. Furthermore, the application demonstrates the cannabinoid can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function. Dr. Eric Hsu, Senior VP Pre-Clinical Research & Development at InMed, described as encouraging the data demonstrating the potential for using a rare cannabinoid to enhance neuronal function and offer neuroprotection to treat neurodegenerative diseases. “This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs,” continued Hsu. According to the Harvard NeuroDiscovery Center, 5 million Americans currently suffer from Alzheimer’s Disease, 1 million from Parkinson’s Disease, 400,000 from multiple sclerosis (“MS”), 30,000 from Lou Gehrig’s Disease, and a further 30,000 from Huntington’s Disease. In addition, the center estimates that if left unchecked, three decades from now, more than 12 million Americans will suffer from neurodegenerative diseases, which primarily strike in mid- to late-life (https://ibn.fm/UB26K). Globally, 135 million people are expected to be affected by Alzheimer’s disease alone by 2050, up from 40 million in 2015. Neurodegenerative diseases are also projected to increase the individual, social, and financial burden of taking care of the patients. For instance, the projected economic impact of Alzheimer’s Disease in the United States alone is expected to reach about $1 trillion per year in 2050, according to the 2017 G7 Academies’ Joint Statements (https://ibn.fm/5Tf7a). Based on these factors, the Harvard NeuroDiscovery Center notes that finding treatments and cures is a matter of increasing urgency. InMed’s patent application is, therefore, a promising start. The application expands InMed’s patent portfolio, which currently includes twelve patent families, and demonstrates its commitment to pharmaceutical programs and the potential of rare cannabinoids in medicine. Furthermore, being an international patent law treaty, the PCT provides InMed with a unified procedure for filing patent applications to protect its invention in each of the 153 member countries. Notably, the rare cannabinoid that forms the basis of the PCT is new to InMed’s portfolio. This showcases the company’s continued commitment to researching the therapeutic benefits of rare cannabinoids as well as producing rare cannabinoids for various uses. With more than 140 rare cannabinoids that occur in low amounts in the cannabis plant, InMed observes that the cost of extracting sufficient quantities can be prohibitive. Even so, the company has unparalleled cannabinoid manufacturing expertise, anchored in three manufacturing approaches – biosynthesis, chemical synthesis, and IntegraSyn(TM) (https://ibn.fm/rmxs1) – that gives it complete flexibility to select the most suitable, cost-effective method to produce a high-quality and pure rare cannabinoid fit for the intended purpose. Importantly, BayMedica, InMed’s most recent acquisition, is continuing to develop an expanding library of patentable, new cannabinoid analogs targeting diverse clinical applications. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Global cannabis market estimated to reach $19.89 billion in 2021, projected to grow at a CAGR of 27%
• North America projected to record the highest market share during the forecast period
• SGMD is expanding role as a central player in growing California cannabis delivery marketplace, developing in-house cannabis production capacity

As growing numbers of consumers around the world become more aware of the potential benefits of cannabis, the market is projected to see significant growth. A new report notes that the global cannabis market is estimated to grow at a CAGR of 27.0% from 2021 to 2030 (https://ibn.fm/c3OpZ). That anticipated growth has not gone unnoticed by Sugarmade (OTC: SGMD), a product and brand marketing company focused on expanding its end-market access as a central player in the growing California cannabis space. “The global cannabis market has been estimated to reach a value of USD $19.89 billion in 2021 and it is projected to grow at a CAGR of 27.0% during the forecast period,” stated the Quince Market Insights report. “The market growth can be attributed can be attributed to the rising awareness among customers concerning the health advantages of cannabis and its increasing medical application. “The growth factors identified in the market are the proven medicinal effects of cannabis, legalization of cannabis, developments in intellectual property rights of cannabis, and active research and development and modification of the plant,” the article continued. “As the threat and concern of coronavirus continue in communities, the cannabis industry emerges to be growing. The government all around the world are taking initiatives to legalize cannabis because of its numerous medicinal advantages like treatment of chronic diseases is an important factor increasing the development of the cannabis market.” The report categorized the global cannabis market into five main areas: North America, Europe, Asia Pacific, Middle East and Africa, and South America, with North America “projected to record the highest market share during the forecast period. The medical application of cannabis is observing remarkable development as customers are becoming more conscious about the medicinal advantages of cannabis,” the article stated. “According to the U.S. Government Accountability Officer, conditions and symptoms that can be treated by cannabis include Alzheimer’s diseases, HIV-AIDS, anorexia, arthritis, nausea, pain, Crohn’s disease, migraines, and multiple sclerosis. Continuous research and standardization of products for medicinal purposes are anticipated to raise the popularity and demand for cannabis in the future.” Sugarmade has set its eyes on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while also developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade is working to develop a full farm-to-door vertically integrated cannabis business. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD